当前位置: 首页 >> 检索结果
共有 87780 条符合本次的查询结果, 用时 5.5885757 秒

1141. My Brother's Keeper.

作者: Joshua A Budhu.
来源: N Engl J Med. 2025年392卷24期2399-2401页

1142. Coadministered Cagrilintide and Semaglutide in Adults with Overweight or Obesity.

作者: W Timothy Garvey.;Matthias Blüher.;Cynthia Karenina Osorto Contreras.;Melanie J Davies.;Eva Winning Lehmann.;Kirsi H Pietiläinen.;Domenica Rubino.;Paolo Sbraccia.;Thomas Wadden.;Niels Zeuthen.;John P H Wilding.; .
来源: N Engl J Med. 2025年393卷7期635-647页
Semaglutide at a dose of 2.4 mg has established weight-loss and cardiovascular benefits, and cagrilintide at a dose of 2.4 mg has shown promising results in early-phase trials; the efficacy of the combination (known as CagriSema) on weight loss in persons with either overweight and coexisting conditions or obesity is unknown.

1143. Cagrilintide-Semaglutide in Adults with Overweight or Obesity and Type 2 Diabetes.

作者: Melanie J Davies.;Harpreet S Bajaj.;Christa Broholm.;Astrid Eliasen.;W Timothy Garvey.;Carel W le Roux.;Ildiko Lingvay.;Christian Bøge Lyndgaard.;Julio Rosenstock.;Sue D Pedersen.; .
来源: N Engl J Med. 2025年393卷7期648-659页
Cagrilintide and semaglutide have each been shown to induce weight loss as monotherapies. Data are needed on the coadministration of cagrilintide and semaglutide (called CagriSema) for weight management in adults with type 2 diabetes, including those in a subgroup who are undergoing continuous glucose monitoring.

1144. Regulatory Policy to Address Ultraprocessed Foods.

作者: Dariush Mozaffarian.
来源: N Engl J Med. 2025年392卷24期2393-2396页

1145. Stem Cell-Derived, Fully Differentiated Islets for Type 1 Diabetes.

作者: Trevor W Reichman.;James F Markmann.;Jon Odorico.;Piotr Witkowski.;John J Fung.;Martin Wijkstrom.;Fouad Kandeel.;Eelco J P de Koning.;Anne L Peters.;Chantal Mathieu.;Leslie S Kean.;Bote G Bruinsma.;Chenkun Wang.;Molly Mascia.;Bastiano Sanna.;Gautham Marigowda.;Felicia Pagliuca.;Doug Melton.;Camillo Ricordi.;Michael R Rickels.; .
来源: N Engl J Med. 2025年393卷9期858-868页
Zimislecel is an allogeneic stem cell-derived islet-cell therapy. Data on the safety and efficacy of zimislecel in persons with type 1 diabetes are needed.

1146. Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.

作者: Ravindra Uppaluri.;Robert I Haddad.;Yungan Tao.;Christophe Le Tourneau.;Nancy Y Lee.;William Westra.;Rebecca Chernock.;Makoto Tahara.;Kevin J Harrington.;Arkadiy L Klochikhin.;Irene Braña.;Gustavo Vasconcelos Alves.;Brett G M Hughes.;Marc Oliva.;Iane Pinto Figueiredo Lima.;Tsutomu Ueda.;Tomasz Rutkowski.;Ursula Schroeder.;Paul-Stefan Mauz.;Thorsten Fuereder.;Simon Laban.;Nobuhiko Oridate.;Aron Popovtzer.;Nicolas Mach.;Yevhen Korobko.;Diogo Alpuim Costa.;Anupama Hooda-Nehra.;Cristina P Rodriguez.;R Bryan Bell.;Cole Manschot.;Kimberly Benjamin.;Burak Gumuscu.;Douglas Adkins.; .
来源: N Engl J Med. 2025年393卷1期37-50页
The benefit of the addition of perioperative pembrolizumab to standard care with surgery and adjuvant therapy for patients with locally advanced head and neck squamous-cell carcinoma (HNSCC) is unclear.

1147. Revised Recommendations for Covid-19 Vaccines - U.S. Vaccination Policy under Threat.

作者: Jason L Schwartz.
来源: N Engl J Med. 2025年393卷5期417-419页

1148. Biologic Drugs and Medicare Price Negotiation.

作者: Thomas J Hwang.;Nancy L Keating.;Stacie B Dusetzina.
来源: N Engl J Med. 2025年393卷1期6-9页

1149. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply.

作者: Anneke C Hesseling.;H Simon Schaaf.;Susan E Purchase.
来源: N Engl J Med. 2025年392卷23期2391-2392页

1150. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis. Reply.

作者: Greg J Fox.;Nguyen Viet Nhung.;Guy B Marks.
来源: N Engl J Med. 2025年392卷23期2390-2391页

1151. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

作者: Mao-Shui Wang.
来源: N Engl J Med. 2025年392卷23期2390页

1152. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

作者: Ronald Lubelchek.
来源: N Engl J Med. 2025年392卷23期2389-2390页

1153. Levofloxacin for the Prevention of Multidrug-Resistant Tuberculosis.

作者: Saul Malozowski.
来源: N Engl J Med. 2025年392卷23期2389页

1154. Oral Infigratinib Therapy in Children with Achondroplasia. Reply.

作者: Ravi Savarirayan.;Daniela Rogoff.
来源: N Engl J Med. 2025年392卷23期2388-2389页

1155. Oral Infigratinib Therapy in Children with Achondroplasia.

作者: Gustavo Rico-Llanos.;Aleksandra A Czyrek.;Pavel Krejci.
来源: N Engl J Med. 2025年392卷23期2388页

1156. Oral Infigratinib Therapy in Children with Achondroplasia.

作者: Stefan Bittmann.
来源: N Engl J Med. 2025年392卷23期2387-2388页

1157. Three Cases of Vertical Transmission of Clade Ib Mpox Virus.

作者: Emmanuel Hasivirwe Vakaniaki.;Nono-Raymond Swar Kuispond.;Yuichiro Hirata.;Eugene Bangwen.;Isabel Brosius.;Eddy Kinganda-Lusamaki.;Seiya Ozono.;Harutaka Katano.;Laurent Gabanga Ndunge.;Noella Mulopo-Mukanya.;Jean-Claude Tshomba.;Elise De Vos.;Christophe Van Dijck.;Papy Munganga.;Guy Mukari.;Yves Mujula.;Divin Mazambi Mambo.;Steeven Bilembo Kitwanda.;Nadine Maliyamungu-Bubala.;Léandre Mutimbwa-Mambo.;Ian Crozier.;Lori E Dodd.;Olivier Tshiani-Mbaya.;Bienvenu Massamba Lebwaze.;Espoir Bwenge Malembaka.;Isaac Barhishindi.;Susanne Krasemann.;Robert Colebunders.;Patrick D M C Katoto.;Sheila Makiala-Mandanda.;Jason Kindrachuk.;Anne W Rimoin.;Jean-Jacques Muyembe-Tamfum.;Daniel Mukadi-Bamuleka.;Tony Wawina-Bokalanga.;Sabin Sabiti Nundu.;Tadaki Suzuki.;Raphaël Bulakali Chirimwami.;Laurens Liesenborghs.;Placide Mbala-Kingebeni.
来源: N Engl J Med. 2025年392卷23期2385-2387页

1158. Myasthenia Gravis - Redemption for B-Cell Depletion.

作者: Gil I Wolfe.;Shahar Shelly.
来源: N Engl J Med. 2025年392卷23期2382-2384页

1159. Nonoperative Management of dMMR Tumors - A Patient-Centered Approach.

作者: Elena Elez.
来源: N Engl J Med. 2025年392卷23期2380-2382页

1160. Case 17-2025: A 61-Year-Old Man with Respiratory Failure and Shock after Kidney Transplantation.

作者: Camille N Kotton.;Rory L Cochran.;Alan M Sanders.;Kassem Safa.;Maxwell T Roth.
来源: N Engl J Med. 2025年392卷23期2368-2378页
共有 87780 条符合本次的查询结果, 用时 5.5885757 秒